Trinity Biotech and Latch Medical Forge Strategic Alliance to Combine AI-Powered CGM Biosensing with Intradermal Drug Delivery for Metabolic Disease
Key Insights
Trinity Biotech and Latch Medical announced a strategic collaboration to integrate CGM+ wearable biosensor data with the Pharma Latch™ intradermal drug delivery platform for metabolic conditions.
The partnership aims to develop precision therapeutic solutions for diabetes (search), obesity (search), and other metabolic diseases by using real-time biosensor data to guide drug delivery.
Trinity Biotech has agreed in principle to make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors (search).
Trinity Biotech plc (NASDAQ: TRIB) and Latch Medical Limited (search) have entered into a strategic collaboration agreement aimed at developing next-generation precision therapeutic solutions for metabolic diseases, the companies announced on July 22, 2026. The partnership will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's proprietary Pharma Latch™ hollow microneedle-based intradermal drug delivery technology, with an initial focus on diabetes (search), obesity (search), and other metabolic conditions.
The collaboration represents a convergence of continuous biosensing, artificial intelligence, and precision drug delivery — an integration that both companies believe could enable more personalized and responsive therapeutic interventions.
"We believe the future of metabolic healthcare lies at the intersection of advanced biosensing, artificial intelligence and precision drug delivery," said John Gillard, Chief Executive Officer of Trinity Biotech. "Our vision for CGM+ extends beyond monitoring alone. We see the opportunity to create a platform capable of generating actionable metabolic intelligence that can help guide therapeutic interventions and improve patient outcomes."
Exploring Biosensor-Guided Therapeutic Delivery
Under the collaboration, the companies will evaluate how real-time metabolic data generated by the CGM+ platform can be used to guide and optimize therapeutic delivery via the Pharma Latch™ system. The Pharma Latch™ platform is a hollow microneedle-based intradermal drug delivery technology designed to enable precise, reliable, and repeatable administration of injectable therapies into the skin. It is engineered to support a broad range of liquid formulations and clinically relevant drug volumes in both clinical and at-home settings.
The CGM+ platform, which incorporates AI-native capabilities, recently generated positive clinical trial data on the identification of nocturnal compression lows, providing a foundation for its expanded application beyond glucose monitoring alone.
Strategic Investment and Market Vision
As part of the agreement, Trinity Biotech has agreed in principle to make a strategic equity investment in Latch Medical, which has previously attracted investment from established participants in the global drug delivery industry. Trinity Biotech's largest financial investor, Perceptive Advisors (search), is supporting the planned investment.
Ronan Byrne, Chief Executive Officer of Latch Medical, welcomed the partnership: "Trinity Biotech's vision for advanced metabolic monitoring creates an exciting opportunity to explore how biosensing and precision drug delivery technologies can work together. We are delighted to welcome Trinity Biotech as both a strategic collaborator and shareholder."
Building an Integrated Metabolic Health Platform
The collaboration supports Trinity Biotech's broader strategy of building an integrated metabolic health platform that combines continuous sensing, AI-driven insights, and precision therapeutic delivery. Management views the convergence of these technologies as representing a significant long-term opportunity within large and growing metabolic disease markets.
Gillard further emphasized the strategic rationale: "By combining our AI-native CGM+ platform with Latch Medical's innovative precision drug delivery technology, we have an exciting opportunity to explore a new generation of metabolic health solutions. Our strategic collaboration and investment reflect our conviction that integrating advanced biosensing, AI and precision drug delivery has the potential to enable more personalised and responsive therapeutic interventions."
The Pharma Latch™ products remain in development and pre-approval stages and are not yet available for sale in the United States, European Union, or any other jurisdiction. The Pharma Latch HCP device (Pharma Latch Hollow) is currently being prepared for regulatory submission.